brain diseases News
-
Altoida to Present at Upcoming Industry Conferences
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, 10:30 – 11:30 am ET Location: ...
-
Lauren Sciences LLC awarded second grant for LAUR-401 from Voices Against Brain Cancer
New York, New York, February 7, 2017 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart™ Nanomedicines for brain diseases, today announced the award of its second grant from Voices Against Brain Cancer (VABC). VABC grant will support Lauren Sciences continued development of LAUR-401, its novel V-Smart™ Nanomedicine for Glioblastoma ...
-
Lauren Sciences awarded grant by Voices Against Brain Cancer to develop V-Smart Nanomedicine for GBM
New York, New York, June 30, 2015 -- Lauren Sciences LLC, the private New York biotechnology company developing breakthrough V-Smart™ Nanomedicines for brain diseases, announced today the award of a grant by Voices Against Brain Cancer (VABC). VABC funding will support the development of a V-Smart™ for glioblastoma multiforme (GBM). The future success of V-Smart™ for GBM should ...
-
Lauren Sciences LLC awarded second grant for LAUR-301 from The ALS Association
New York, N.Y., April 19, 2016 -- Lauren Sciences LLC, private New York biotechnology company developing breakthrough V-SmartTM Nanomedicines for brain diseases, announced today award of second grant from The ALS Association. The ALS Association grant will support Lauren Sciences continued development of LAUR-301, its V-SmartTM Nanomedicine designed for ALS (amyotrophic lateral sclerosis), also ...
-
Lauren Sciences LLC awarded third grant for LAUR-301 from The ALS Association
New York, N.Y., April 11, 2018 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart® Nanomedicines for brain diseases, today announced the award of its third grant from The ALS Association. The ALS Association grant will support Lauren Sciences continued development of LAUR-301, its novel V-Smart® Nanomedicine for ALS (amyotrophic lateral ...
-
Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. Inscopix offers innovative miniature-microscope (miniscope) based imaging ...
-
Altoida Appoints Neuroscience Pioneer Dr. Antontella Santuccione Chadha as Chief Medical Officer
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer. In this new role, Dr. Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize ...
-
BrainScope Advances its Commercial Adoption and Appoints Industry Veteran Susan Hertzberg as CEO
BrainScope announced today the appointment of Susan Hertzberg as Chief Executive Officer. This is the 4th equity-backed venture that Hertzberg will helm. She is a proven commercial stage leader with an impressive track record of bringing innovative products and services to market and profitably scaling and delivering exceptional market growth. In her new role, Hertzberg will drive the global ...
-
Agilent Technologies and Daegu Gyeongbuk Institute of Science and Technology Collaborate on Neurometabolomics Research
Agilent Technologies Inc. (NYSE: A) and the Daegu Gyeongbuk Institute of Science and Technology today announced a strategic collaboration with the opening of the DGIST's new Neurometabolomics Excellence Research Center. The center will use Agilent's bio-analytical instruments in its neurometabolomics research of biomarkers for early detection and diagnosis of brain diseases. DGIST is one of ...
-
Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer’s Disease
Optina Diagnostics announces today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its retinal imaging platform (CAPRS1/MHRC2). Optina Diagnostics’ platform uses Artificial Intelligence (AI) to analyze the data rich hyperspectral retinal images captured with the MHRC during a simple eye scan. Optina Diagnostics’ platform is intended for ...
-
Oxford Brain Diagnostics awarded FDA Breakthrough Device Designation for technology to predict Alzheimer’s Disease
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease Oxford Brain ...
-
Inscopix Expands Applications with Blood Flow Imaging to Study Relationship between Brain Activity and Vascular Dynamics
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other debilitating ...
-
Neurolutions IpsiHand Stroke Rehabilitation Device Authorized by FDA
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use in patients 18 and older undergoing stroke rehabilitation to facilitate muscle re-education and for maintaining or increasing range of motion. The Neurolutions IpsiHand Upper Extremity Rehabilitation System (IpsiHand System) is a Brain-Computer-Interface (BCI) device that assists in rehabilitation ...
By Neurolutions
-
Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart Platform, and selected as a Featured Company, in new report by MCD Group
New York, N.Y., June 18, 2013 -- Lauren Sciences, a privately-held biotechnology company furthering development of its novel V-Smart™ nanovesicle platform technology, announced today that it was independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in a new report by MCD Group. The report, "Early Stage Drug ...
-
BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has received FDA clearance to include additional language in its product’s Indications for Use (IFU), adding key terminology related to “multi-modal, multi-parameter assessment" of “concussion" and “mild Traumatic Brain ...
-
The Hitchhiker’s Guide to Survival Analysis
Survival analysis is the best thing in the world since sliced bread! However, in most machine learning circles, it’s pretty much synonymous with an “# it’scomplicated” relationship status. Survival Analysis is an Extremely Valuable Branch of Statistics We want our guide to better serve you as a straightforward go-to/how-to, eliminating any confusion. The guide provides a ...
By JADBio
-
DiamiR Biosciences Announces Participation in Alzheimer`s Panel at the BioFuture 2022 Conference
DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that the company's management will participate in the BioFuture Conference being held on November 7-9, 2022 at the Lotte New York Palace in New York City, NY. Kira Sheinerman, Ph.D., Co-Founder and Executive Director, will be a participant in the panel discussion, "New approvals, ...
By DiamiR
-
Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24.8 million
2021 Optina, an innovative diagnostics company leading the field of Retinal Imaging, Brain Health and Systemic Diseases Diagnostics, announced today the closing of an CA$24.8 million Series A round of funding. Optina’s Retinal Deep Phenotyping™ platform obtained FDA Breakthrough Device Designation status in 2019 for its non-invasive and more accessible test to improve diagnosis ...
-
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. “We are excited that the FDA has granted UB-311 Fast Track ...
By Vaxxinit
-
Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you